Sectra Reports Enterprise Imaging Solution Now Covers Majority of Midwest Patients Following New Contract

Sectra

International medical imaging IT and cybersecurity company Sectra (STO: SECT B) will provide its enterprise imaging solution to yet another healthcare provider in the Midwest. The healthcare provider will utilize the radiology module to unify the management of approximately two million images across multiple states and over 20 sites, streamlining their imaging strategy. It also signifies a key achievement for Sectra, as most patients in the region will now be served through a Sectra solution, enabling the new customer to collaborate with other regional health systems if needed.

Transitioning to one single solution will offer the healthcare provider several advantages. It will accelerate physician access to critical information, leading to faster and more accurate diagnoses for patients. It will also streamline radiology operations, simplify IT management, and enable scalability and expansion into other specialties.

Isaac Zaworski, Company President

“Collaborating across sites and providing efficient radiology workflows are needed to cope with the increasing imaging volumes. This new customer is the 60th healthcare provider to use Sectra in the US Midwest and I’m pleased to be continuing our work in this area. With our local experience as well as our knowledge in providing multi-site solutions for large organizations we will help them on this journey in the best way possible.”

The contract for Sectra’s enterprise imaging solution was signed during the third quarter of Sectra’s 2023/2024 fiscal year and the healthcare provider will initially use the solution’s module for radiology. The contracted order value amounts to $15.7 million of which $14.3 is guaranteed. The order entails an on-premises installation along with 5 years of support and maintenance.

SourceSectra

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”